Coronary disease & ACSRandomised controlled trial
Effect of evolocumab on saphenous vein graft patency after coronary artery bypass surgery (NEWTON-CABG CardioLink-5): an international, randomised, double-blind, placebo-controlled trial
- Randomised controlled trial
- multicentre
- double-blind
- placebo-controlled
- 23 sites in Canada, the USA, Australia, and Hungary
Authors' conclusion
Among patients who underwent CABG, evolocumab did not reduce SVG disease at 24 months following the index surgery despite substantial LDL-C lowering.
Study context
- Population
- Adults after coronary artery bypass graft (CABG) with ≥2 saphenous vein graft (SVGs) on moderate- or high-intensity statin therapy554 with primary outcome data
- Participants
- 782 adults
- Comparison
- Evolocumab vs placebo
- Evolocumabn = 389
- Placebon = 393reference
- Primary endpoint
- Vein graft disease rate (VGDR; proportion of SVGs with ≥50% occlusion on coronary CT angiography or clinically indicated invasive angiography)
- Follow-up
- 24 months
Primary result
VGDR
Difference
2.0%
95% CI −3.1 to 7.1
P = 0.44
Events by treatment group
Evolocumab vs Placebo
difference 2.0% (95% CI −3.1 to 7.1); P = 0.44
As reported in the abstract
Further findings
| Outcome | Evolocumab | Placebo | mean placebo-adjusted reduction |
|---|---|---|---|
| LDL-C change · 24 months | −52.4% | −4.0% | 48.4% |
Safety
Adverse events
- Well tolerated, similar adverse event profiles between groups
Original publication
Effect of evolocumab on saphenous vein graft patency after coronary artery bypass surgery (NEWTON-CABG CardioLink-5): an international, randomised, double-blind, placebo-controlled trial. Lancet. Published 1 September 2025. doi:10.1016/s0140-6736(25)01633-2
Summarised from the published abstract; every number is checked against it